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Abstract
In the last few years, much progress in avoiding acute and chronic rejection in trans-
planted patients has been made by introducing new and more effective drugs with dif-
ferent formulations and combinations, and fewer side effects. Standardized protocols 
have been proposed for different organs, but individualized therapy based on immuno-
suppressive therapy blood monitoring is necessary because of pharmacological interac-
tion, new generic drug introductions, and different absorptions and biodistributions. In 
specific mycophenolate mofetil dosing through mycophenolic acid (MPA), therapeutic 
drug monitoring has demonstrated minimal risk of organ transplant rejection. Even if 
the MPA area under the 12 h concentration–time curve is more accurate than MPA levels, 
it appears to be resource consuming and clinically impractical because of the need for 
numerous blood samples. Limited sampling strategy (LLS) has been proposed to over-
come this problem. In heart-transplanted patients, MPA LSS is useful in guiding clinical 
management and dosing. The purpose of this chapter is to describe the state of the art of 
MPA LSS employment in heart transplantation and to perform an update of the scientific 
literature.
Keywords: heart transplantation, immunosuppressive therapy, mycophenolate mofetil, 
therapeutic drug monitoring, limited sampling strategy
1. Introduction
After heart transplantation, it is usual to administer the triple-drug therapy of induction 
and maintenance with calcineurin inhibitor (CNI), tacrolimus (TAC) or cyclosporine (CsA), 
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mycophenolate mofetil (MMF)/enteric-coated mycophenolate sodium (EC-MPS), prodrugs 
of mycophenolic acid (MPA) or everolimus (EVE)/sirolimus (SIR) and corticosteroids (CSs). 
TAC should be the preferred CNI and MMF/EC-MPS the preferred cell cycle inhibitor [1]. 
Baraldo et al., in their review, concluded that CS withdrawal is safe in 50–80% of patients, 
with late withdrawal being better than early withdrawal. In addition, CS avoidance should 
be advisable and mandatory in pediatric patients, elderly patients and patients with insulin-
dependent diabetes mellitus, metabolic disorders, osteoporosis and infections [2]. While for 
CNI or mTOR, therapeutic drug monitoring (TDM) is a clinical practice, MPA TDM is already 
controversial and is not widely used. One of the reasons is that in laboratories it was not 
a widely distributed platform for the analysis of plasma MPA concentrations, compared to 
other immunosuppressive drugs such as CsA, TAC, SIR and EVE. Moreover, this drug was 
promoted as not necessary for TDM and so generally MMF was administered as a fixed dose 
regimen. However, it was demonstrated that a >10-fold range in MPA dose-normalized area 
under the curve (AUC) between patients may be observed in heart, renal and liver transplan-
tation, so MPA TDM may be useful [3]. Finally, since it has been demonstrated that the correct 
use of MPA TDM would require several blood samples to define the AUC0–12, this approach appeared to be laborious, costly and clinically impractical [4]. To overcome the practical prob-
lems linked to blood samples to obtain an AUC0–12, limited sampling strategies (LSSs) have been proposed. In a recent Consensus Meeting, LSSs were preferred in solid organ transplan-
tation compared with drug dosing that is based on MPA through concentrations, and the 
individualization of MMF dosing may minimize the risk of organ transplant rejection [5]. So 
the MPA-AUC0–12 obtained using the LSS may be useful to guide clinical management and dosing. With the increasing use of MPA in solid organ transplantation, the greater possibility 
of analyzing at lower costs and the greater diffusion of laboratories that are able to perform 
the analysis have been recently revised for kidney transplantation [6]. The purpose of this 
chapter is to describe the state of the art of studies to calculate MPA LSSs in heart transplant 
recipients and to perform an update of the scientific literature.
2. Mycophenolate mofetil
MMF (Cell Cept®, Roche Pharmaceuticals, Basel, Switzerland) is the morpholino ester pro-
drug of MPA and was approved by the Food and Drug Administration in May 1995. MMF 
became a routine and extensively used part of immunosuppressive regimens, in combina-
tion with other immunosuppressant medications, after kidney transplantation, but it is 
also used after heart, lung, heart/lung and liver transplantation [7]. Attention was focused 
on the gastrointestinal side effects associated with its use, and an alternative formulation 
of MPA was explored in an effort to reduce the burden of gastrointestinal toxicity. An 
enteric-coated formulation of MPA (EC-MPS, Myfortic®, Novartis Pharma AG, Basel, 
Switzerland) was developed [8]. Equimolar doses of EC-MPS and MMF were shown to 
produce equivalent MPA exposure and to result in inhibition of the activity of the target 
enzyme inosine-5-monophosphate dehydrogenase (IMPDH) to a similar degree [9]. The 
patents have expired for MMF and EC-MPS. Because MPA is not considered a narrow 
therapeutic index drug, the wider bio-equivalence criteria are applied for the registration 
of generic MMF formulations [10].
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2.1. Pharmacodynamics and pharmacokinetics
MMF is rapidly metabolized to its active constituent MPA, which acts as a specific inhibitor 
of the proliferation of T- and B-lymphocytes by reversibly inhibiting IMPDH, the key enzyme 
of the de novo purine synthesis in activated lymphocytes. The inhibition of T- and B-cell 
proliferation results in diminished cytotoxic T-cell responses and antibody formation against 
the allograft [11].
MPA bioavailability is >90%. It is mainly metabolized by uridine 5′-diphospho--glucurono-
syltransferase [mycophenolic acid glucuronide (MPAG)] in the liver, intestine and kidney 
in 7-O-glucuronide (inactive) and acyl-glucuronide (active). MPA and MPAG are bound to 
the protein 97–99 and 82%, respectively, MPA metabolites are eliminated by the kidney and 
MPA and MPAG are subject to enterohepatic recirculation. The mean ‘apparent’ half-life and 
plasma clearance of MPA are 17.9 h and 11.6 L/h, respectively, after oral administration [12].
The clinical pharmacokinetics (PK) of MPA are characterized by a high between-subject and 
within-subject variability. It also was noted in all types of solid organ transplantation that 
dose-normalized MPA exposure in the first 3 months after transplantation was increased. 
The increase in MPA exposure can range from 30–80%. The coadministration of immunosup-
pressive or other drugs may influence MPA exposure. The MPA-AUC0–12 and its glucuronide 
metabolite were higher in patients with renal impairment than in patients with normal renal 
function following single dose administration. The MMF PK after a single dose is not altered 
in patients with cirrhosis. The main side effects of MPA are gastrointestinal disturbances, 
hematological disorders (e.g. anemia and leucopenia) and infections [13–15].
Moreover, it has been demonstrated that genetic polymorphisms may influence MMF absorp-
tion, distribution, metabolism and pharmacological action and may contribute to this interin-
dividual variation in MMF response [16].
3. Mycophenolate mofetil after heart transplantations
Early preclinical studies of MMF demonstrated that MMF significantly prolonged cardiac 
transplants in rats and that the combination of MMF with CsA was more effective than either 
agent alone [17]. Furthermore, some trials suggest that MMF, when substituted for azathio-
prine in standard triple-drug therapy regimens, is well tolerated and might be more efficacious 
than azathioprine [18–20]. This could be explained by the hypothesis that MMF may provide 
more synergy with concomitantly administered cyclosporine and/or CSs than azathioprine, 
therefore demonstrating benefits to both renal [18–22] and cardiac transplant populations. 
Also, MMF has novel properties that may contribute to the prevention of cardiac allograft rejec-
tion and provide benefits in reducing the progression of vascular allograft vasculopathy (CAV).
3.1. Drug administration
Some findings have attempted to correlate MMF pharmacokinetic parameters with outcomes. 
MMF is a prodrug, so it is rapidly hydrolysed after ingestion to MPA. It must be administered 
on an empty stomach. TDM in patients receiving MMF has not been extensively investigated, 
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although preclinical studies demonstrated a correlation between MPA levels and histologic 
severity of graft rejection. In addition, because appreciable within-patient fluctuations may 
occur, the dose should not be changed based on a single predose measurement. Another 
important point is the balance between the different immunosuppressive agents. For exam-
ple, in previous studies, the risk of rejection was similar between groups with either a higher 
CsA level and a lower MMF dose or a lower CsA level and a higher MMF dose [23].
3.2. Trials supporting MMF
In 1993, Ensley et al. [18] published one of the first clinical reports describing the use of MMF 
in cardiac transplantation. This was the first study that found MMF effective to significantly 
reduce the mean biopsy score with less myelosuppression compared to azathioprine. Some 
years later, Kobashigawa et al. [24] published the first large multicentre trial in 1998. At the 
time the trial was initiated, immunosuppressive regimens for heart transplantation relied 
on a combination of CsA, steroids and azathioprine. The use of MMF demonstrated better 
survival rates at 1 and 5 years. After these promising results, an analysis of data from the 
Joint ISHLT/United Network for Organ Sharing Thoracic Registry was conducted in 2001 [25] 
where the improved long-term survival benefit of MMF therapy was confirmed, suggesting 
that the positive findings are broadly applicable within the cardiac transplant population. 
In addition to the randomized, multicentre trials [26–28], other trials and studies evaluated 
MMF in cardiac transplant recipients in combination with either CsA [29–32] or TAC [30] and 
in CNI-sparing regimens [33–35]. For example, other studies evaluating the combination of 
MMF with TAC were published, aimed at determining whether trough-level-adjusted MMF 
was more effective in combination with TAC or CsA. These results showed that the incidence 
of acute rejections was lower in patients receiving TAC versus the CsA group, although there 
was no difference in patient survival. Results from the most recent multicentre, randomized 
trial involving MMF in cardiac transplant recipients were presented at the ISHLT annual 
meeting in 2005 [36]. Hence, these authors concluded that in cardiac transplant patients, TAC/
MMF appears to offer advantages over TAC/SRL or CsA/MMF when considering any treated 
rejection and side-effect profiles.
3.3. Advantages and side effects of MMF therapy
Therapy with MMF has peculiar advantages. In patients with chronic renal dysfunction, the 
reduction in CNI exposure, either through dose reduction or complete withdrawal, has been 
studied as a means of minimizing further deterioration of renal function. For this purpose, 
MMF-based CNI-sparing strategies were evaluated in three trials with promising results 
[34, 35, 37]. A second aspect is related to the anti-inflammatory properties of MMF that may 
provide long-term benefits in reducing the risk of CAV in cardiac transplant recipients. 
Furthermore, Weis et al. [37] reported that in cardiac transplant patients the combination of 
TAC/MMF appeared to be superior to TAC/azathioprine in preserving early coronary vaso-
motor function, endothelial nitric oxide synthase expression and inducible nitric oxide syn-
thase suppression, as well as cardiac interleukin-6 release. Since these factors, in addition to 
the risks posed by rejection, are believed to be predictors of CAV, MMF may have a beneficial 
impact on the subsequent development of CAV.
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Being a selective inhibitor of inosine monophosphate dehydrogenase, it is common to have 
some side effects. The most commonly reported side effects of MMF include leukopenia, ane-
mia, infections, systemic cytomegalovirus disease, hypercholesterolemia and gastrointestinal 
complications such as diarrhea, nausea and dyspepsia. On the other hand, malignant neo-
plasms, especially of the skin, are frequent in patients treated with MMF [38, 39].
4. Therapeutic drug monitoring of MPA
Several studies have suggested that therapeutic drug monitoring of MPA concentrations in 
patients with renal, heart or lung transplants may improve clinical outcomes and allow effec-
tive dose individualization of MMF potentially minimizing toxicity [3, 40–43]. In heart trans-
plant recipients, several studies have shown that MPA levels correlate to the risk of rejection 
[44, 45]. AUC0–12 seems to be a better parameter to optimize MPA treatment than the predose measurement (C0). Unfortunately, measuring AUC0–12 requires the collection and analysis of multiple blood samples, which is costly and time-consuming for patients and clinical staff. 
So, AUC0–12 measurement could be simplified by using a technique, initially developed for anticancer drugs, called LSS [46, 47]. It was shown that an equation using three blood samples 
measured at specific times could approximate or estimate the real AUC0–12. An AUC0–12 thresh-old of 50 mg × h/L was proposed (sensitivity = 77%, specificity = 25%) beyond which the risk 
of rejection was significantly increased (low vs. high: HR = 3.48 [1.21–10.0], p = 0.0204) [48].
4.1. Analysis of MPA
Quantification of MPA may be performed by high-performance liquid chromatography 
(HPLC) with ultraviolet detection, liquid chromatography-mass spectrometry (LC–MS/MS) 
or a commercially available platform assay. In general, laboratories that are providing a rou-
tine TDM service will tend to use the platform immunoassay. Those with a large number of 
sample loads and those with research interests are likely to use the chromatographic tech-
nique. HPLC with MS detection is often described as the gold standard technique [49, 50]. 
One of the problems that can create a bias and alter the calculation of the nomograms are the 
analytical methods used. It has now been demonstrated that MPA plasma concentrations mea-
sured by the immunoassay technique are higher than those determined by HPLC by 25–36%. 
This overestimation is most likely attributable to the cross-reactivity of the pharmacologically 
active acyl-glucoronide (Ac MPAG).
4.2. Limited sampling strategy
LSS is a technique aimed at estimating the AUC0–12 using a small number of samples, usually three or fewer. Modeling the relationship between the pharmacokinetic parameter and the 
drug concentration at various times allows this reduction in the number of samples required. 
The model can then be used to choose the best sampling times to determine the parameter 
accurately and precisely. The development of such a method requires full pharmacokinetic 
profiles drawn with sufficient points to measure AUC0–12 accurately. Most authors use the trapezoidal method, but there is also linear trapezoidal and linear-logarithmic trapezoidal. 
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The differences observed between methods are small and there is no clinical significance. To 
develop an LSS, the first step is arbitrarily splitting the patient data into two groups: a training 
group and a testing or validation group. The training group is used to determine the relation-
ship between AUC0–12 and the timed blood concentration data using a linear regression. The AUC0–12 is considered to be the dependent variable; the independent variables are the blood concentrations at each time point. An equation is defined giving the AUC0–12 as a function of one or several concentrations:
  AUC 0–12  = Constant +  ( M 1 ×  C 1 ) +  ( M 2 ×  C 2 ) +  ( M 3 ×  C 3 ) +  ( M x ×  C x ) 
where AUC0–12 is the predicted AUC0–12, constant is the intercept on the y-axis, C1, C2, C3, Cx are the blood concentrations measured at time 1, 2, 3, x and M1, M2, M3, Mx are the associated coef-ficients. The equations are then validated using the testing group. Validation is a compulsory 
step that must be carried out on a different group to the training group because testing an 
equation on the group of patients used to generate the equation itself would be self-fulfilling 
and therefore would produce biased results. Using a fresh data set allows the equations to be 
tested under real conditions, thus helping in the decision about which equations should be 
used and which should not. The performance of the equations can be assessed by comparing 
the predicted AUC0–12 with the measured AUC0–12 measuring the mean prediction error or bias (me) and the root mean squared prediction error or precision (rmse) with their confidence 
intervals (CIs). The smaller these parameters, the better the prediction [51]. A simpler assess-
ment of the performance of the equations can be achieved by estimating the percentage pre-
diction error (%pe) on the AUC0–12, defined as ([predicted value − measured value]/measured value) times 100. A more clinically orientated method consists of evaluating the proportion 
of AUC0–12 estimated within a percentage prediction error range. Another method consists of expressing the results using the absolute prediction error for a certain percentile of predic-
tions. Some authors ‘validated’ their equations by calculating the correlation coefficient (r) or 
coefficient of determination (r) between the predicted AUC0–12 and the measured AUC0–12. This method should not be used because it gives biased results [52].
5. Limited sampling strategy in heart transplants: an upgrade
A search of MEDLINE was done for papers on heart transplantation, MPA and LSS. The fol-
lowing search terms were used: mycophenolic acid, mycophenolate mofetil, heart transplant, 
solid organ transplant and limited sampling strategy. We utilized this filter: human, adult and 
English. We considered only papers with these inclusion criteria: age > 18 years, heart trans-
plantation, cotreatment with CyA or TAC and CSs, heart-training group, heart-testing group 
and plasma MPA concentrations analysed by HPLC. We excluded papers with: age < 18 years, 
kidney, lung, liver, pancreas transplantations and plasma MPA concentrations analysed by 
enzyme-multiplied immunoassay technique (EMIT). We found only five studies published, 
presented in Table 1, where we reported studies with the same analytical assay (HPLC) and 
the nomogram with a coefficient of determination r2 > 0.80.
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In 2005, Baraldo et al. wrote the first paper on the use of LSSs to estimate the AUC in heart 
transplant patients. This was one of two papers that utilized correctly training group and 
validation group. The authors studied a population with these characteristics: adult >18 years, 
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5.57 + 0.90 * C1.25 + 2.02 * 
C2 + 4.59 * C6
3.8 + 1.03 * C1.25 + 1.82 * 
C2 + 1.57 * C4 + 3.48 * C6
5.57 + 0.90 * C1.25 + 2.02 * 
C2 + 4.59 * C6
3.8 + 1.03 * C1.25 + 1.82 * 











11 0.10 + 11.15 * C0 + 0.42 * 
C1 + 2.80 * C2
1.28 + 1.91 * C1 + 0.26 * 
C2 + 5.91 * C4
−0.51 + 11.47 * C0 + 3.24 * C2









28 1.25 * C1 + 5.29 * C4 + 2.90 * 
C8 + 3.61 * C10
1.33 * C1 + 3.99 * C4 + 3.23 * 
C6 + 3.81 * C8
1.53 * C1 + 5.51 * C4 + 4.62 
* C8
3.93 * C1 + 3.99 * C4 + 3.23 * 
C6 + 3.81 * C8
3.37 * C0 + 0.97 * C0.5 + 1.20 * 
C1 + 2.70 * C2














9.69 + 0.63 * C0.5 + 0.61 * C1 + 2.20 * C2
7.93 + 3.89 * C0 + 0.87 * C1 + 1.02 * C2 + 3.72 * C4









AUC = area under the curve; r2 = coefficient of determination; CsA = cyclosporine; HPLC = high-performance liquid 
chromatography; TAC = tacrolimus.
Table 1. Limited sampling strategy suggested for MPA-AUC monitoring in combination with cyclosporine A or 
tacrolimus in heart transplantation.
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CsA and steroids and good kidney and liver functions. The analysis of MPA plasma concen-
trations was by HPLC. Multiple stepwise regression analysis was used to define the time 
points of MPA levels to explain the MPA-AUC0–12. Agreement between abbreviated AUC0–12 and full AUC0–12 was tested by means of a Bland and Altman analysis. Stepwise linear regres-sion showed that the minimal model with the best estimation of MPA-AUC0–12 was obtained at time values of 1.25, 2 and 6 h. The corresponding estimated model was AUC0–12 = 5.568 + 0.902 * C(1.25) + 2.022 * C(2) + 4.594 * C(6) (r2 = 0.926). Bland and Altman analysis revealed good 
agreement between predicted AUC0–12 and full AUC0–12. A further interesting model equa-tion obtained by four samples was AUC0–12 = 3.800 + 1.015 * C(1.25) + 1.819 * C(2) + 1.566 * C(4) + 3.479 * C(6) (r2 = 0.948) [53]. To obtain the validation, these two algorithms proposed 
were tested in a validation group (29 heart transplant recipients) with the same characteristics 
of the testing group. The two LSS algorithms used predicted the corresponding MPA-AUC0–12 with a mean bias of −4.85 and −3.6% and mean precision of 15.9 and 14%, respectively. Baraldo 
et al. in conclusion revealed that the MPA-AUC0–12 obtained using the LSS may be useful to 
guide clinical management and dosing, but in heart transplant recipients who share the same 
characteristics [54].
The study of Wada et al. published in 2007 studied 22 Japanese heart transplant patients 
approximately 9 months after transplantation and divided them into two groups: 11 who 
were given MMF + CsA and 11 who were given MMF + TAC. They calculated the entire MPA-
AUC0–12 and developed an LSS. They suggested a model consisting of three time points and another with two time points that predicted the entire MPA-AUC0–12. We have utilized these two algorithms in heart transplant patients treated with MMF-CsA. The results obtained 
from this study, however, should be taken with caution because of the limited number of 
patients evaluated and the ethnic difference, which could influence MPA pharmacokinetics. 
The patients studied were given the same regimen therapy, the analytical method used was 
HPLC and the same pharmacokinetic and statistical approaches were used [55].
In 2008, Kaczmarek et al. studied 28 heart transplant patients treated with MMF and TAC. For 
each patient, the entire MPA-AUC0–12 was studied using an LSS. The best estimation of MPA-AUC0–12 was obtained with four sampling points: AUC = 1.25 * C1 + 5.29 * C4 + 2.90 * C8 + 3.61 * C10 (r2 = 0.95). The three sampling point equation within the first 2 h was preferred for ambu-latory patients: AUC = 1.1 * C0.5 + 1.16 * C1 + 3.72 * C2 (r2 = 0.84). The population studied was long-term adult heart transplant recipients (2.5 ± 3 years) with chronic maintenance of 
immunosuppressive therapy consisting of MMF and TAC [56].
The most recent publication that defined algorithms for the TDM of MPA in heart transplant 
patients was by Pawinski et al. [57]. The authors studied 20 patients in a first step to obtain a 
sampling strategy and 24 patients in a second step to validate the algorithms. The regression 
equation for AUC estimation that gave the best fit was: AUC = 9.69 + 0.63 * C0.5 + 0.61 * C1 + 2.20 * C2 (r2 = 0.841; me = 3.2%; CI 95% (−42.2%; 40.3%)). This global approach appears correct. However, there are some issues that must be discussed: (1) from a statistical point of view, 
the CI of the me is quite wide; (2) the authors calculated the algorithms within the range of 
6–8 weeks to 1 year after heart transplant and validated the algorithms in patients more than 
1 year after heart transplant, periods that might be characterized by different pathophysi-
ological conditions and concomitant therapy; and (3) the algorithms that include the C
6
 blood 
sample presented the same r2 = 0.841 and should be considered [58].
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Moreover, the study by Dosch et al. presented single-centre preliminary analysis data and is 
one of the largest published investigations of MPA-AUC0–12 in heart transplant recipients to date. The authors, however, did not calculate the entire AUC0–12, and used algorithms taken from the literature with algorithms calculated in renal-transplanted patients. Furthermore, 
MPA plasma concentrations were measured by means of Emit Mycophenolic Acid Assay, 
which gives slightly higher concentration results compared to HPLC [59].
Ting et al. evaluated 25 heart transplant patients and estimated the MPA-AUC0–12. They used an LSS previously developed for lung transplant recipients as well as an LSS used for 
heart transplant patients published from a different author. The authors concluded that the 
previously developed LSS used for lung transplant recipients performed well when applied 
to the heart transplant population for the prediction of MPA-AUC, while the application 
of the LSS obtained from the literature yielded fewer optimal results. Their conclusion was 
that: (1) LSS appears to be centre specific, (2) LSS should always be validated before imple-
mentation and (3) LSS should be limited to the population and drug therapy that were used 
to develop it [60].
6. Conclusions
This update has highlighted that research on MPA TDM by LSS in heart-transplanted patients 
was exhausted in 2009. Over the last 10 years, prevalent MPA TDM by LSS studies have been 
developed in kidney transplants and revised by van Gelder [6]. From the last Consensus 
Report, MPA TDM based on LSSs is preferred in solid organ transplantation compared 
to drug dosing that is based on single MPA trough concentrations. LSS is associated with 
early postoperative efficacy. The data suggest that specific patient populations might benefit 
from LSSs to reduce immunological risk in patients who are undergoing minimization or 
withdrawal of immunosuppressive therapy and patients who are experiencing altered renal, 
hepatic or bowel function [5]. Even though there is scientific support of its importance, the 
analysis of MPA plasma concentrations, LLS or Bayesian methodologies is not currently 
applied on a routine basis after heart transplant, and studies from heart transplant patients 
remain limited [53–57].
The most recent publication that defined algorithms for the TDM of MPA in heart transplant 
patients was by Pawinski et al. [57]. The authors calculated the algorithms within the range 
of 6–8 weeks to 1 year after heart transplant and validated the algorithms in patients more 
than 1 year after heart transplant. The two periods cannot be compared because the former is 
more or less rich in clinical problems and drugs, while the latter is usually characterized by a 
clinical stationarity and fewer medications taken.
Kaczmarek et al. studied 28 heart transplant patients treated with MMF and TAC [56]; the 
population studied was long-term adult heart transplant recipients (2.5 ± 3 years). These algo-
rithms cannot be compared with MMF-CyA. An algorithm calculated from a TAC + MPA 
association cannot be used for a CsA + MPA association.
The study of Wada et al. considered patients with the same regimen therapy, analyti-
cal method (HPLC) and pharmacokinetic and statistical approaches [55]. In this study the 
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approach appears well designed; however, ethnic differences could influence MPA pharma-
cokinetics, create a bias and generate nomograms that cannot be used for other ethnic groups. 
It appears that with the same dosage, MPA systemic exposure is higher in Asian renal trans-
plant patients than in Caucasians and American-Africans [61].
Papers by Baraldo et al., ideation groups 2005 and validation groups 2009 are the only studies 
performed in the first 6 months after transplantation, which are the months where the greatest 
variability is observed and are the most critical months for the graft [53, 54]. In the Consensus 
of 2010, the group of experts cited the Kaczmarek, Baraldo and Ting papers, predicting them 
as reference works for the algorithms in heart transplants. One of the limitations of this study 
was the limited number of patients in the ideation group [5].
When using the LSS to estimate the MPA-AUC, it is important that the study populations 
(ideation group and validation group), the drugs and the analytical methods used have char-
acteristics that are always the same and repeatable. Bayesian methodologies have multiple 
advantages, are more adaptable to different types of patients and are less sensitive to inac-
curacies in sampling time [4, 62]. As a result the application of a nomogram from an LSS to 
estimate AUC0–12 is simpler to use but requires greater precision, while Bayesian methodolo-gies are more difficult to use and a specialized technician is required.
Thanks to research done on kidney transplants, today there are automated LC–MS/MS plat-
forms on the market that can perform MPA plasma analysis more accurately, in less time 
and the costs of the analyses have been significantly reduced. Therefore, there is currently a 
greater possibility of performing the MPA TDM and a personalization of the therapy.
More accurate MPA TDM may reduce the leukopenia that often leads to discontinua-
tion of MMF therapy and increased risk of rejection. Therefore, in heart transplantations 
it may be concluded that: (1) the guidelines recommend a C0 of 1–3.5 mg/L and MPA-AUC0–12 values of 30–60 mg · h/L; (2) a population is used similar to that for the calculation of the nomogram (type of transplant, post-transplant period, used therapy, ethnicity, etc.); 
and (3) analysis of the MPA is performed with a method similar to that used to calculate 
the nomogram of the LSS.
In conclusion, these results are interesting because LSS MPA-AUC0–12 in heart transplant 
patients remains a sector of clinical pharmacology seldom studied and completes our previ-
ous findings with a validation group showing valuable bias and precision values. Future 
studies are needed to determine whether these algorithms can be clinically applied in 
a larger cohort of heart transplant patients receiving CsA or TAC associated with MPA 
therapy.
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